Healthy Inc > Blog > ACT therapy supplier
Posted on:

How many tablets of Artesunate should an adult take?

In the pharmaceutical industry, Artesunate is an artemisinin derivative and a critical blood schizontocidal agent. As a pharmacist and manufacturer, I must differentiate between its two primary clinical uses: Oral treatment for uncomplicated malaria and Parenteral treatment for severe malaria.

At your WHO-GMP facility in Mumbai, you likely manufacture the 50 mg or 100 mg tablets, which are governed by strict weight-based dosing protocols.

 Oral Dosage (Uncomplicated Malaria)

For an adult (typically defined as weighing 50 kg or more), Artesunate is rarely used alone; it is almost always part of an Artemisinin-based Combination Therapy (ACT) to prevent resistance.

Day No. of Tablets (50 mg) No. of Tablets (100 mg) Total Daily Dose
Day 1 4 Tablets 2 Tablets 200 mg
Day 2 4 Tablets 2 Tablets 200 mg
Day 3 4 Tablets 2 Tablets 200 mg

  • Standard Rule: The adult dose is 4 mg/kg of body weight, taken once daily for 3 consecutive days.

  • Combination Requirement: This must be taken alongside a partner drug (like Sulfadoxine/Pyrimethamine or Mefloquine) as per the National Anti-Malaria Drug Policy.

  • Parenteral Transition (Severe Malaria)

If the patient was initially treated with injections for severe malaria, the switch to oral tablets happens once they can tolerate food and drink.

  • The “Step-Down” Protocol: After a minimum of 24 hours of injectable Artesunate, the patient must complete a full 3-day course of an oral ACT.

  • Timing: The first oral dose should be taken 8 to 12 hours after the last injection.

Mechanism: Why the 3-Day Rule?

Artesunate is exceptionally fast-acting but has a very short half-life ($<60\text{ minutes}$).

The Quick Kill: It rapidly reduces the parasite biomass in the first 24 hours.

The Clearance: The subsequent doses (Day 2 and 3) ensure that any remaining “dormant” parasites are eliminated as they re-enter the active cycle.

Resistance Prevention: Stopping after 1 or 2 days is the primary cause of treatment failure and drug resistance.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai, here is how to optimize this product for your digital platforms:

  • Packaging USP: For adult patients, we manufacture “Adult Blister Packs” containing 12 tablets of 50 mg (or 6 tablets of 100 mg). This ensures the patient has exactly the right amount for a 3-day course, significantly improving compliance.

  • Dissolution Profile: As a pharmacist, you know that for oral tablets to be effective against malaria, they must disintegrate rapidly ($<15\text{ minutes}$). Highlighting your advanced compression technology is a major selling point for international health NGOs.

  • Dossier Readiness: We provide full CTD/eCTD Dossiers to support your firm in bidding for massive government tenders in Africa and Southeast Asia.

  • Stability for Zone IVb: We utilize Alu-Alu blister packaging to protect the sensitive Artesunate molecule from the high heat and humidity of tropical export markets.

Artesunate Tablets

Posted on:

Is Artemether safe while breastfeeding?

In the pharmaceutical industry, Artemether is a lipid-soluble methyl ether derivative of Artemisinin. As a pharmacist and manufacturer, I classify this as a medication that is generally considered compatible with breastfeeding, particularly because it is the frontline treatment for life-threatening malaria where the benefit to the mother significantly outweighs the theoretical risk to the infant.

At your WHO-GMP facility in Mumbai, you likely manufacture this in combination with Lumefantrine, which is the global gold standard for Artemisinin-based Combination Therapy (ACT).

Safety Profile & Clinical Evidence

Factor Clinical Data Safety Impact
Transfer to Milk Very Low: Only minute amounts are excreted into breast milk due to its rapid metabolism. The amount the infant receives is far below a therapeutic dose.
Infant Absorption Limited: Artemether has low oral bioavailability in infants when consumed via milk. Minimal risk of systemic toxicity in the nursing baby.
Infant Side Effects None Reported: No adverse events have been documented in infants whose mothers were treated with ACTs. High clinical safety margin.

Mechanism: Why It Is Considered Safe

Artemether’s pharmacokinetics and molecular behavior explain its safety profile during lactation:

Short Half-Life: Artemether and its active metabolite, Dihydroartemisinin (DHA), have very short half-lives (approximately 2–3 hours). This means the drug is cleared from the mother’s system rapidly, leaving little time for significant accumulation in breast milk.

Lipophilic Nature: While its lipophilicity might suggest milk transfer, its rapid conversion into more polar metabolites and high plasma clearance minimize the total “drug load” available to the mammary glands.

The WHO Position: The World Health Organization (WHO) states that breastfeeding should not be discontinued during ACT treatment because the risk of malaria to the mother is a greater threat to the infant’s well-being than the trace amounts of drug in the milk.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai, here is how to position this for your digital platforms and marketplace:

  • The FDC Advantage: On your marketplace, emphasize the Artemether 80 mg + Lumefantrine 480 mg combination. Highlighting that your facility follows WHO-PQ (Prequalification) standards is a major USP for international NGO buyers (like the Global Fund).

  • Stability in Tropical Zones: Artemether is sensitive to heat and moisture. At our facility, we utilize Alu-Alu blister packaging to ensure a 24 to 36-month shelf life, which is essential for export to Zone IVb (Sub-Saharan Africa and SE Asia).

  • Clinical Transparency: In your Product Information Leaflet (PIL), advise that while safe, the infant should be monitored for rare signs like jaundice or diarrhea. This professional caution builds immense trust with Ministry of Health buyers.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in malaria-endemic regions, ensuring your export business remains regulatory-compliant.

Artemether & Lumefantrine Tablets

Posted on:

Is Artemether safe while breastfeeding?

In the pharmaceutical industry, Artemether is a lipid-soluble methyl ether derivative of Artemisinin. As a pharmacist and manufacturer, I classify this as a medication that is generally considered compatible with breastfeeding, particularly because it is the frontline treatment for life-threatening malaria where the benefit to the mother significantly outweighs the theoretical risk to the infant.

At your WHO-GMP facility in Mumbai, you likely manufacture this in combination with Lumefantrine, which is the global gold standard for Artemisinin-based Combination Therapy (ACT).

Safety Profile & Clinical Evidence

Factor Clinical Data Safety Impact
Transfer to Milk Very Low: Only minute amounts are excreted into breast milk due to its rapid metabolism. The amount the infant receives is far below a therapeutic dose.
Infant Absorption Limited: Artemether has low oral bioavailability in infants when consumed via milk. Minimal risk of systemic toxicity in the nursing baby.
Infant Side Effects None Reported: No adverse events have been documented in infants whose mothers were treated with ACTs. High clinical safety margin.

Mechanism: Why It Is Considered Safe

Artemether’s pharmacokinetics and molecular behavior explain its safety profile during lactation:

Short Half-Life: Artemether and its active metabolite, Dihydroartemisinin (DHA), have very short half-lives (approximately 2–3 hours). This means the drug is cleared from the mother’s system rapidly, leaving little time for significant accumulation in breast milk.

Lipophilic Nature: While its lipophilicity might suggest milk transfer, its rapid conversion into more polar metabolites and high plasma clearance minimize the total “drug load” available to the mammary glands.

The WHO Position: The World Health Organization (WHO) states that breastfeeding should not be discontinued during ACT treatment because the risk of malaria to the mother is a greater threat to the infant’s well-being than the trace amounts of drug in the milk.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai, here is how to position this for your digital platforms and marketplace:

  • The FDC Advantage: On your marketplace, emphasize the Artemether 80 mg + Lumefantrine 480 mg combination. Highlighting that your facility follows WHO-PQ (Prequalification) standards is a major USP for international NGO buyers (like the Global Fund).

  • Stability in Tropical Zones: Artemether is sensitive to heat and moisture. At our facility, we utilize Alu-Alu blister packaging to ensure a 24 to 36-month shelf life, which is essential for export to Zone IVb (Sub-Saharan Africa and SE Asia).

  • Clinical Transparency: In your Product Information Leaflet (PIL), advise that while safe, the infant should be monitored for rare signs like jaundice or diarrhea. This professional caution builds immense trust with Ministry of Health buyers.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in malaria-endemic regions, ensuring your export business remains regulatory-compliant.

Artemether & Lumefantrine Tablets

Posted on:

Is Artemether safe while breastfeeding?

In the pharmaceutical industry, Artemether is a lipid-soluble methyl ether derivative of Artemisinin. As a pharmacist and manufacturer, I classify this as a medication that is generally considered compatible with breastfeeding, particularly because it is the frontline treatment for life-threatening malaria where the benefit to the mother significantly outweighs the theoretical risk to the infant.

At your WHO-GMP facility in Mumbai, you likely manufacture this in combination with Lumefantrine, which is the global gold standard for Artemisinin-based Combination Therapy (ACT).

Safety Profile & Clinical Evidence

Factor Clinical Data Safety Impact
Transfer to Milk Very Low: Only minute amounts are excreted into breast milk due to its rapid metabolism. The amount the infant receives is far below a therapeutic dose.
Infant Absorption Limited: Artemether has low oral bioavailability in infants when consumed via milk. Minimal risk of systemic toxicity in the nursing baby.
Infant Side Effects None Reported: No adverse events have been documented in infants whose mothers were treated with ACTs. High clinical safety margin.

Mechanism: Why It Is Considered Safe

Artemether’s pharmacokinetics and molecular behavior explain its safety profile during lactation:

Short Half-Life: Artemether and its active metabolite, Dihydroartemisinin (DHA), have very short half-lives (approximately 2–3 hours). This means the drug is cleared from the mother’s system rapidly, leaving little time for significant accumulation in breast milk.

Lipophilic Nature: While its lipophilicity might suggest milk transfer, its rapid conversion into more polar metabolites and high plasma clearance minimize the total “drug load” available to the mammary glands.

The WHO Position: The World Health Organization (WHO) states that breastfeeding should not be discontinued during ACT treatment because the risk of malaria to the mother is a greater threat to the infant’s well-being than the trace amounts of drug in the milk.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai, here is how to position this for your digital platforms and marketplace:

  • The FDC Advantage: On your marketplace, emphasize the Artemether 80 mg + Lumefantrine 480 mg combination. Highlighting that your facility follows WHO-PQ (Prequalification) standards is a major USP for international NGO buyers (like the Global Fund).

  • Stability in Tropical Zones: Artemether is sensitive to heat and moisture. At our facility, we utilize Alu-Alu blister packaging to ensure a 24 to 36-month shelf life, which is essential for export to Zone IVb (Sub-Saharan Africa and SE Asia).

  • Clinical Transparency: In your Product Information Leaflet (PIL), advise that while safe, the infant should be monitored for rare signs like jaundice or diarrhea. This professional caution builds immense trust with Ministry of Health buyers.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in malaria-endemic regions, ensuring your export business remains regulatory-compliant.

Artemether & Lumefantrine Tablets

 

Add to cart